Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 8/2015

01.07.2015 | Original Article

Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous 18F-fluorocholine PET/MRI for primary prostate cancer characterization

verfasst von: Yong-il Kim, Gi Jeong Cheon, Jin Chul Paeng, Jeong Yeon Cho, Cheol Kwak, Keon Wook Kang, June-Key Chung, Euishin Edmund Kim, Dong Soo Lee

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to determine the usefulness of MRI-assisted positron emission tomography (PET) parameters provided by simultaneous 18F-fluorocholine (FCH) PET/MRI for characterization of primary prostate cancer.

Methods

Thirty patients with localized prostate cancer (mean age 69.4 ± 6.7 years) confirmed by biopsy were prospectively enrolled for simultaneous PET/MRI imaging. The patients underwent 18F-FCH PET/MRI 1 week before undergoing total prostatectomy. Multiple parameters of diffusion-weighted MRI [minimum and mean apparent diffusion coefficient (ADCmin and ADCmean)], metabolic PET [maximum and mean standardized uptake value (SUVmax and SUVmean)], and metabolic volumetric PET [metabolic tumor volume (MTV) and uptake volume product (UVP)] were compared with laboratory, pathologic, and immunohistochemical (IHC) features of the prostate cancer specimen. PET parameters were divided into two categories as follows: volume of interest (VOI) of prostate by SUV cutoff 2.5 (SUVmax, SUVmean, MTVSUV, and UVPSUV) and MRI-assisted VOI of prostate cancer (SUVmaxMRI, SUVmeanMRI, MTVMRI, and UVPMRI).

Results

The rates of prostate cancer-positive cases identified by MRI alone, 18F-FCH PET alone, and 18F-FCH PET/MRI were 83.3, 80.0, and 93.3 %, respectively. Among the multiple PET/MRI parameters, MTVMRI showed fair correlation with serum prostate-specific antigen (PSA; r = 0.442, p = 0.014) and highest correlation with tumor volume (r = 0.953, p < 0.001). UVPMRI showed highest correlation with serum PSA (r = 0.531, p = 0.003), good correlation with tumor volume (r = 0.908, p < 0.001), and it was significantly associated with Gleason score (p = 0.041). High MTVMRI and UVPMRI values were significant for perineural invasion, lymphatic invasion, extracapsular extension, seminal vesicle invasion, and positive B-cell lymphoma 2 (Bcl-2) expression (all p < 0.05).

Conclusion

Simultaneous 18F-FCH PET/MRI demonstrated a better diagnostic value for localized prostate cancer detection than each individual modality. MRI-assisted metabolic volumetric PET parameters (MTVMRI and UVPMRI) provided more accurate characterization of prostate cancer than conventional PET and MRI parameters.
Literatur
1.
3.
Zurück zum Zitat Takahashi N, Inoue T, Lee J, Yamaguchi T, Shizukuishi K. The roles of PET and PET/CT in the diagnosis and management of prostate cancer. Oncology 2007;72:226–33.PubMedCrossRef Takahashi N, Inoue T, Lee J, Yamaguchi T, Shizukuishi K. The roles of PET and PET/CT in the diagnosis and management of prostate cancer. Oncology 2007;72:226–33.PubMedCrossRef
4.
Zurück zum Zitat Ahmed HU, Kirkham A, Arya M, Illing R, Freeman A, Allen C, et al. Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 2009;6:197–206.PubMedCrossRef Ahmed HU, Kirkham A, Arya M, Illing R, Freeman A, Allen C, et al. Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 2009;6:197–206.PubMedCrossRef
7.
9.
Zurück zum Zitat Evangelista L, Zattoni F, Guttilla A, Saladini G, Zattoni F, Colletti PM, et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med 2013;38:305–14.PubMedCrossRef Evangelista L, Zattoni F, Guttilla A, Saladini G, Zattoni F, Colletti PM, et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med 2013;38:305–14.PubMedCrossRef
10.
Zurück zum Zitat Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol 2013;31:427–35.PubMedCrossRef Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol 2013;31:427–35.PubMedCrossRef
11.
Zurück zum Zitat Sauter AW, Wehrl HF, Kolb A, Judenhofer MS, Pichler BJ. Combined PET/MRI: one step further in multimodality imaging. Trends Mol Med 2010;16:508–15.PubMedCrossRef Sauter AW, Wehrl HF, Kolb A, Judenhofer MS, Pichler BJ. Combined PET/MRI: one step further in multimodality imaging. Trends Mol Med 2010;16:508–15.PubMedCrossRef
12.
Zurück zum Zitat Pace L, Nicolai E, Aiello M, Catalano OA, Salvatore M. Whole-body PET/MRI in oncology: current status and clinical applications. Clin Transl Imaging 2013;1:31–44.CrossRef Pace L, Nicolai E, Aiello M, Catalano OA, Salvatore M. Whole-body PET/MRI in oncology: current status and clinical applications. Clin Transl Imaging 2013;1:31–44.CrossRef
13.
Zurück zum Zitat Lee SJ, Seo HJ, Cheon GJ, Kim JH, Kim EE, Kang KW, et al. Usefulness of integrated PET/MRI in head and neck cancer: a preliminary study. Nucl Med Mol Imaging 2014;48:98–105.PubMedCentralPubMedCrossRef Lee SJ, Seo HJ, Cheon GJ, Kim JH, Kim EE, Kang KW, et al. Usefulness of integrated PET/MRI in head and neck cancer: a preliminary study. Nucl Med Mol Imaging 2014;48:98–105.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Wetter A, Lipponer C, Nensa F, Beiderwellen K, Olbricht T, Rübben H, et al. Simultaneous 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results. Invest Radiol 2013;48:256–62.PubMedCrossRef Wetter A, Lipponer C, Nensa F, Beiderwellen K, Olbricht T, Rübben H, et al. Simultaneous 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results. Invest Radiol 2013;48:256–62.PubMedCrossRef
15.
Zurück zum Zitat Wetter A, Lipponer C, Nensa F, Heusch P, Rübben H, Altenbernd JC, et al. Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F]choline PET/CT. Eur J Nucl Med Mol Imaging 2014;41:79–88.PubMedCrossRef Wetter A, Lipponer C, Nensa F, Heusch P, Rübben H, Altenbernd JC, et al. Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F]choline PET/CT. Eur J Nucl Med Mol Imaging 2014;41:79–88.PubMedCrossRef
16.
Zurück zum Zitat Chang JH, Lim Joon D, Lee ST, Hiew CY, Esler S, Gong SJ, et al. Diffusion-weighted MRI, 11C-choline PET and 18F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma. Eur Radiol 2014;24:715–22.PubMedCrossRef Chang JH, Lim Joon D, Lee ST, Hiew CY, Esler S, Gong SJ, et al. Diffusion-weighted MRI, 11C-choline PET and 18F-fluorodeoxyglucose PET for predicting the Gleason score in prostate carcinoma. Eur Radiol 2014;24:715–22.PubMedCrossRef
17.
Zurück zum Zitat Wetter A, Lipponer C, Nensa F, Heusch P, Rübben H, Schlosser TW, et al. Quantitative evaluation of bone metastases from prostate cancer with simultaneous [18F] choline PET/MRI: combined SUV and ADC analysis. Ann Nucl Med 2014;28:405–10.PubMedCrossRef Wetter A, Lipponer C, Nensa F, Heusch P, Rübben H, Schlosser TW, et al. Quantitative evaluation of bone metastases from prostate cancer with simultaneous [18F] choline PET/MRI: combined SUV and ADC analysis. Ann Nucl Med 2014;28:405–10.PubMedCrossRef
18.
Zurück zum Zitat Yoneyama T, Tateishi U, Terauchi T, Inoue T. Correlation of metabolic tumor volume and 11C-choline uptake with the pathology of prostate cancer: evaluation by use of simultaneously recorded MR and PET images. Jpn J Radiol 2014;32:155–63.PubMedCrossRef Yoneyama T, Tateishi U, Terauchi T, Inoue T. Correlation of metabolic tumor volume and 11C-choline uptake with the pathology of prostate cancer: evaluation by use of simultaneously recorded MR and PET images. Jpn J Radiol 2014;32:155–63.PubMedCrossRef
19.
Zurück zum Zitat Rahim MK, Kim SE, So H, Kim HJ, Cheon GJ, Lee ES, et al. Recent trends in PET image interpretations using volumetric and texture-based quantification methods in nuclear oncology. Nucl Med Mol Imaging 2014;48:1–15.PubMedCentralPubMedCrossRef Rahim MK, Kim SE, So H, Kim HJ, Cheon GJ, Lee ES, et al. Recent trends in PET image interpretations using volumetric and texture-based quantification methods in nuclear oncology. Nucl Med Mol Imaging 2014;48:1–15.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol 1986;31:229–34.PubMedCrossRef Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol 1986;31:229–34.PubMedCrossRef
21.
Zurück zum Zitat von Eyben FE, Kairemo K. Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun 2014;35:221–30.CrossRef von Eyben FE, Kairemo K. Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun 2014;35:221–30.CrossRef
22.
Zurück zum Zitat Fuccio C, Rubello D, Castellucci P, Marzola MC, Fanti S. Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol 2011;80:e50–6.PubMedCrossRef Fuccio C, Rubello D, Castellucci P, Marzola MC, Fanti S. Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol 2011;80:e50–6.PubMedCrossRef
23.
Zurück zum Zitat Schwarzenböck S, Souvatzoglou M, Krause BJ. Choline PET and PET/CT in primary diagnosis and staging of prostate cancer. Theranostics 2012;2:318–30.PubMedCentralPubMedCrossRef Schwarzenböck S, Souvatzoglou M, Krause BJ. Choline PET and PET/CT in primary diagnosis and staging of prostate cancer. Theranostics 2012;2:318–30.PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Lütje S, Boerman OC, van Rij CM, Sedelaar M, Helfrich W, Oyen WJ, et al. Prospects in radionuclide imaging of prostate cancer. Prostate 2012;72:1262–72.PubMedCrossRef Lütje S, Boerman OC, van Rij CM, Sedelaar M, Helfrich W, Oyen WJ, et al. Prospects in radionuclide imaging of prostate cancer. Prostate 2012;72:1262–72.PubMedCrossRef
25.
Zurück zum Zitat Romesser PB, Lim R, Spratt DE, Setton J, Riaz N, Lok B, et al. The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [(18)F] fluorodeoxyglucose positron emission tomography scan. Oral Oncol 2014;50:802–8.PubMedCrossRef Romesser PB, Lim R, Spratt DE, Setton J, Riaz N, Lok B, et al. The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [(18)F] fluorodeoxyglucose positron emission tomography scan. Oral Oncol 2014;50:802–8.PubMedCrossRef
26.
Zurück zum Zitat Kim YI, Cheon GJ, Paeng JC, Cho JY, Kang KW, Chung JK, et al. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate–high risk adrenal incidentaloma. Nucl Med Commun 2014;35:606–12.PubMedCrossRef Kim YI, Cheon GJ, Paeng JC, Cho JY, Kang KW, Chung JK, et al. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate–high risk adrenal incidentaloma. Nucl Med Commun 2014;35:606–12.PubMedCrossRef
27.
Zurück zum Zitat Chung HH, Lee I, Kim HS, Kim JW, Park NH, Song YS, et al. Prognostic value of preoperative metabolic tumor volume measured by 18F-FDG PET/CT and MRI in patients with endometrial cancer. Gynecol Oncol 2013;130:446–51.PubMedCrossRef Chung HH, Lee I, Kim HS, Kim JW, Park NH, Song YS, et al. Prognostic value of preoperative metabolic tumor volume measured by 18F-FDG PET/CT and MRI in patients with endometrial cancer. Gynecol Oncol 2013;130:446–51.PubMedCrossRef
28.
Zurück zum Zitat Byun BH, Noh WC, Lim I, Lee SS, Cho AR, Park JA, et al. A new method for apparent diffusion coefficient measurement using sequential (18)F-FDG PET and MRI: correlation with histological grade of invasive ductal carcinoma of the breast. Ann Nucl Med 2013;27:720–8.PubMedCrossRef Byun BH, Noh WC, Lim I, Lee SS, Cho AR, Park JA, et al. A new method for apparent diffusion coefficient measurement using sequential (18)F-FDG PET and MRI: correlation with histological grade of invasive ductal carcinoma of the breast. Ann Nucl Med 2013;27:720–8.PubMedCrossRef
29.
Zurück zum Zitat Bundschuh RA, Wendl CM, Weirich G, Eiber M, Souvatzoglou M, Treiber U, et al. Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens. Eur J Nucl Med Mol Imaging 2013;40:824–31.PubMedCrossRef Bundschuh RA, Wendl CM, Weirich G, Eiber M, Souvatzoglou M, Treiber U, et al. Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens. Eur J Nucl Med Mol Imaging 2013;40:824–31.PubMedCrossRef
30.
Zurück zum Zitat Schwarzenböck SM, Kurth J, Gocke C, Kuhnt T, Hildebrandt G, Krause BJ. Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer. Eur J Nucl Med Mol Imaging 2013;40:S28–35.PubMedCrossRef Schwarzenböck SM, Kurth J, Gocke C, Kuhnt T, Hildebrandt G, Krause BJ. Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer. Eur J Nucl Med Mol Imaging 2013;40:S28–35.PubMedCrossRef
31.
Zurück zum Zitat Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:1228–42.PubMedCrossRef Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:1228–42.PubMedCrossRef
32.
Zurück zum Zitat Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010;254:925–33.PubMedCrossRef Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010;254:925–33.PubMedCrossRef
33.
Zurück zum Zitat Kitajima K, Murphy RC, Nathan MA. Choline PET/CT for imaging prostate cancer: an update. Ann Nucl Med 2013;27:581–91.PubMedCrossRef Kitajima K, Murphy RC, Nathan MA. Choline PET/CT for imaging prostate cancer: an update. Ann Nucl Med 2013;27:581–91.PubMedCrossRef
34.
Zurück zum Zitat Moul JW. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol 1999;35(5–6):399–407.PubMedCrossRef Moul JW. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol 1999;35(5–6):399–407.PubMedCrossRef
35.
Zurück zum Zitat Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Nijman RJ, et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 2005;32:668–73.PubMedCrossRef Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Nijman RJ, et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 2005;32:668–73.PubMedCrossRef
Metadaten
Titel
Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous 18F-fluorocholine PET/MRI for primary prostate cancer characterization
verfasst von
Yong-il Kim
Gi Jeong Cheon
Jin Chul Paeng
Jeong Yeon Cho
Cheol Kwak
Keon Wook Kang
June-Key Chung
Euishin Edmund Kim
Dong Soo Lee
Publikationsdatum
01.07.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2015
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3026-5

Weitere Artikel der Ausgabe 8/2015

European Journal of Nuclear Medicine and Molecular Imaging 8/2015 Zur Ausgabe